Market closedNon-fractional

Aldeyra Therapeutics/ALDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Aldeyra Therapeutics

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Ticker

ALDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Lexington, United States

Employees

10

ALDX Metrics

BasicAdvanced
$230M
Market cap
-
P/E ratio
-$0.51
EPS
1.44
Beta
-
Dividend rate
$230M
1.44
6.498
3.831
0.182
13.805
-17.02%
-14.29%
-23.94%
2.04
2.04
-7.413
-51.16%
-20.84%

What the Analysts think about ALDX

Analyst Ratings

Majority rating from 8 analysts.
Buy

ALDX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8M
70.21%
Profit margin
0.00%
NaN%

ALDX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 26.55%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.14
-$0.08
-$0.14
-
Expected
-$0.31
-$0.24
-$0.14
-$0.11
-$0.15
Surprise
-51.75%
-41.28%
-42.96%
26.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aldeyra Therapeutics stock?

Aldeyra Therapeutics (ALDX) has a market cap of $230M as of July 23, 2024.

What is the P/E ratio for Aldeyra Therapeutics stock?

The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of July 23, 2024.

Does Aldeyra Therapeutics stock pay dividends?

No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Aldeyra Therapeutics dividend payment date?

Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Aldeyra Therapeutics?

Aldeyra Therapeutics (ALDX) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Aldeyra Therapeutics stock

Buy or sell Aldeyra Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing